Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report

Cross, 2014, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer, Canc. Discov., 4, 1046, 10.1158/2159-8290.CD-14-0337 Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer, N. Engl. J. Med., 378, 113, 10.1056/NEJMoa1713137 Goss, 2016, Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study, Lancet Oncol., 17, 1643, 10.1016/S1470-2045(16)30508-3 Mok, 2017, Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer, N. Engl. J. Med., 376, 629, 10.1056/NEJMoa1612674 Yang, 2017, Osimertinib in pretreated T790M-positive advanced non–small-cell lung cancer: AURA study phase II extension component, J. Clin. Oncol., 35, 1288, 10.1200/JCO.2016.70.3223 Ohe, 2019, Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset, Jpn. J. Clin. Oncol., 49, 29, 10.1093/jjco/hyy179 Akamatsu, 2018, Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial, Canc. Sci., 109, 1930, 10.1111/cas.13623 Camus, 2004, Interstitial lung disease induced by drugs and radiation, Respiration, 71, 301, 10.1159/000079633 Kubo, 2013, Consensus statement for the diagnosis and treatment of drug-induced lung injuries, Respiratory Investigation, 51, 260, 10.1016/j.resinv.2013.09.001 Nagasaka, 2018, Retreatment with osimertinib following pneumonitis, Clin. Lung Canc., 19, e53, 10.1016/j.cllc.2017.06.017 Kiriu, 2018, Successful osimertinib rechallenge with steroid therapy after osimertinib-induced interstitial lung disease, Intern. Med., 57, 91, 10.2169/internalmedicine.8947-17 Miyauchi, 2017, Successful osimertinib rechallenge in a patient with T790M-mutant non-small cell lung cancer after osimertinib-induced interstitial lung disease, J. Thorac. Oncol., 12, e59, 10.1016/j.jtho.2017.01.027 Itano, 2020, Successful Re-administration of osimertinib in osimertinib-induced interstitial lung disease with an organizing pneumonia pattern: a case report and literature review, Intern. Med., 59, 823, 10.2169/internalmedicine.3689-19 Satoh, 2018, Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma, Respir Med Case Rep, 23, 68 Kodama, 2020, Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma, Invest. N. Drugs Arakawa, 2013, Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases, Respirol Case Rep, 1, 17, 10.1002/rcr2.12 Nakamichi, 2013, Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease, Jpn. J. Clin. Oncol., 43, 422, 10.1093/jjco/hyt012 Takeda, 2012, Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC, Jpn. J. Clin. Oncol., 42, 528, 10.1093/jjco/hys042 Nasu, 2020, Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: a retrospective study, Invest. N. Drugs, 38, 1915, 10.1007/s10637-020-00963-w Nishima, 2020, Successful treatment with afatinib after osimertinib-induced interstitial lung disease in a patient with EGFR-mutant non-small-cell lung cancer: a case report, Intern. Med. Gemma, 2020, Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M–positive NSCLC treated with osimertinib in Japan, J. Thorac. Oncol., 15, 1893, 10.1016/j.jtho.2020.08.025